Sarepta Therapeutics Inc (NAS:SRPT)
$ 121.5 -1.87 (-1.52%) Market Cap: 11.61 Bil Enterprise Value: 11.98 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 86/100

Sarepta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 07:00PM GMT
Release Date Price: $155.65 (-2.52%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Sarepta with us this afternoon. We have Doug Ingram, President and CEO; as well as Sandy Mahatme, CFO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Doug, we've seen a rapid evolution of the company over the past few years with Sarepta now positioned as a leader with multiple platforms to address neuromuscular diseases. Can you just walk us through what you see on the horizon when you look out 5 years from today?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. Thank you very much for having us, Salveen. And I've been asked to remind everyone, I will, no doubt, and in taking your the first question, anticipated, I'll be talking about things that may happen in the future. Of course, we -- there are risks and uncertainties

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot